400 related articles for article (PubMed ID: 28319080)
1. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
[TBL] [Abstract][Full Text] [Related]
2. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
5. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
6. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
[TBL] [Abstract][Full Text] [Related]
7. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
[TBL] [Abstract][Full Text] [Related]
8. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
9. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
Iacobelli S; de Wreede LC; Schönland S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N; Gahrton G;
Bone Marrow Transplant; 2015 Apr; 50(4):505-10. PubMed ID: 25621805
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM
Bone Marrow Transplant; 2006 Jun; 37(12):1135-41. PubMed ID: 16757975
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.
Eisfeld C; Eßeling E; Wullenkord R; Khandanpour C; Reusch J; Mikesch JH; Reicherts C; Kerkhoff A; Schliemann C; Kessler T; Mesters RM; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2020 Aug; 99(8):1907-1915. PubMed ID: 32444892
[TBL] [Abstract][Full Text] [Related]
12. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma.
Ringdén O; Shrestha S; da Silva GT; Zhang MJ; Dispenzieri A; Remberger M; Kamble R; Freytes CO; Gale RP; Gibson J; Gupta V; Holmberg L; Lazarus H; McCarthy P; Meehan K; Schouten H; Milone GA; Lonial S; Hari PN
Bone Marrow Transplant; 2012 Jun; 47(6):831-7. PubMed ID: 21946381
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
Kennedy GA; Butler J; Morton J; Hill G; Western R; Cummings J; Allison R; Durrant S
Clin Lab Haematol; 2006 Jun; 28(3):189-97. PubMed ID: 16706936
[TBL] [Abstract][Full Text] [Related]
14. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
15. Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.
Sahebi F; Iacobelli S; Biezen AV; Volin L; Dreger P; Michallet M; Ljungman PT; de Witte T; Henseler A; Schaap NP; López-Corral L; Poire X; Passweg J; Hamljadi RM; Thomas SH; Schonland S; Gahrton G; Morris C; KrÖger N; Garderet L
Bone Marrow Transplant; 2015 Jun; 50(6):802-7. PubMed ID: 25798673
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
[TBL] [Abstract][Full Text] [Related]
17. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
19. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.
Ahmad I; LeBlanc R; Cohen S; Lachance S; Kiss T; Sauvageau G; Roy DC; Busque L; Delisle JS; Bambace N; Bernard L; Sabry W; Roy J
Bone Marrow Transplant; 2016 Apr; 51(4):529-35. PubMed ID: 26691426
[TBL] [Abstract][Full Text] [Related]
20. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
